(Reuters) – Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom’s macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.
(Reporting by Christy Santhosh; Editing by Shounak Dasgupta)
Comments